ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
RALEIGH, N.C., Feb. 04, 2016 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its fourth quarter and year end 2015 results after the market closes on Wednesday, February 24, 2016. The Company will also host a conference call on Thursday, February 25, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 46737204. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 46737204.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, the presentation and an audio playback of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
At PRA Health Sciences, providing innovative solutions for our clients is what we do. Side-by-side with our clients, we strive to move drug discovery forward, helping them to develop life-saving and life-improving drugs. PRA has more than 11,000 employees working in 80+ countries providing comprehensive clinical development services across all phases. From full service clinical development to the pioneering Embedded Solutions™ model, PRA provides a broad spectrum of solutions that meet the demands of a diverse marketplace. As a top five CRO, PRA has worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 50+ such drugs.
INVESTOR INQUIRIES: [email protected] INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +919.786.8463
